Home » Biotechnology » China and Europe Peptide Market

China and Europe Peptide Market By Peptide Type (Signal Peptides, Neurotransmitter Inhibitor Peptides, Carrier Peptides, Enzyme Inhibitor Peptides, Structural Peptides, Synthetic Antimicrobial Peptides (AMPs), Others); By Application (Hair/Eyelash/Eyebrow Care Series, Whitening Series, Anti-Aging Series, Skin Renewal Series, Anti-allergic & Anti-inflammatory Series, Slimming & Breast Enhancement Series, Others); By End Product (Skin Care, Hair Care, Eye Care); By End User (Cosmetic Manufacturers, Cosmetic Contract Manufacturers (OEM/ODM), Biopharmaceutical/Personal Care Industries) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: China and Europe Peptide Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-11-22
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: China and Europe Peptide Market

Summary
Table Of Content
Request Free Sample

Market Overview:

The China and Europe Peptide Market size was valued at USD 10,402.81 million in 2018, increased to USD 23,264.09 million in 2024, and is anticipated to reach USD 63,952.52 million by 2032, at a CAGR of 12.56% during the forecast period.

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
China and Europe Peptide Market Size 2024	USD 23,264.09 Million
China and Europe Peptide Market, CAGR	12.56%
China and Europe Peptide Market Size 2032	USD 63,952.52 Million

Growing demand for targeted therapies drives momentum across China and Europe. Pharmaceutical firms increase research spending to create safe peptide candidates with higher stability and selectivity. Biotech companies scale contract development activities to meet industry need for custom peptide synthesis. Hospitals adopt peptide therapies due to rising chronic disease cases and improved clinical guidelines. Rising government support for biotechnology accelerates trials across metabolic and rare disorders. CDMOs gain strong interest from drug developers that require rapid production cycles. Robust pipelines across oncology and metabolic applications raise long-term demand.

Europe leads adoption due to strong biotech maturity, wide clinical research networks, and strict quality systems that encourage advanced peptide development. China emerges as a high-growth market due to rising R&D funding, supportive regulatory reforms, and fast expansion of domestic biotech firms. Germany, France, and the UK dominate European demand due to strong innovation capacity and broad therapeutic use. China strengthens its position through expanding manufacturing hubs and growing interest in locally developed peptide drugs. Both regions show strong momentum as pharmaceutical groups scale pipelines and research institutes push innovation.

Market Insights:

The China and Europe Peptide Market was valued at USD 10,402.81 million in 2018, reached USD 23,264.09 million in 2024, and is projected to reach USD 63,952.52 million by 2032, expanding at a CAGR of 12.56%.
China holds about 58 share due to strong peptide manufacturing strength, Europe contributes 42% driven by premium skincare demand, and Germany, France, and the UK lead within Europe through advanced R&D and regulatory depth.
China is the fastest-growing region, supported by expanding OEM/ODM networks, high-volume peptide production, and rising consumption across whitening and anti-aging applications.
Structural peptides and carrier peptides together form the largest visible segment group in the chart, reflecting strong use in repair, firmness, and delivery-focused formulations.
Neurotransmitter inhibitor peptides and synthetic antimicrobial peptides show rising share contributions, driven by anti-wrinkle innovation and increased demand for protective and sensitive-skin applications.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Drivers:

Rising Focus on Targeted and Precision Therapeutics

The China and Europe Peptide Market grows due to rising interest in targeted drugs that offer stronger selectivity and lower toxicity profiles. Researchers enhance peptide engineering platforms to support complex mechanisms that improve therapeutic stability. Healthcare providers prefer peptides because they align with clinical practices that emphasize patient safety. Pharmaceutical firms expand biologics pipelines to address unmet needs across oncology and metabolic disorders. Strong investment in peptide synthesis supports scalable production processes. Drug developers adopt high-purity peptide formats to improve trial success rates across major therapeutic areas. It continues to gain traction as demand rises for precision-based medicines across both regions.

For instance, Bachem reported Group sales growth of 8.6% in 2023 (12.8% in local currencies) due to the general increase in the development of targeted peptide therapeutics, and noted that global demand for peptides continues to grow strongly.

Expansion of Clinical Research Networks and R&D Funding

R&D teams expand programs that support peptide discovery across diverse therapeutic categories. European institutes strengthen collaboration models that help early-stage candidates progress into clinical evaluation. China increases R&D spending to support domestic innovation and accelerate translational research. Large hospitals join multi-center trials that encourage rapid adoption of new peptide therapies. Governments create incentives to promote technological advancement and strengthen biotech clusters. Pharmaceutical groups expand licensing activity to secure promising peptide assets. The China and Europe Peptide Market benefits from stronger research ecosystems that encourage continuous development.

For instance, WuXi AppTec significantly expanded its peptide R&D and manufacturing capacity by commissioning two new manufacturing plants in late 2023, bringing its total solid-phase peptide synthesis (SPPS) reactor volume to 32,000 liters by January 2024, and supporting approximately 50 preclinical- to commercial-stage peptide projects in 2023.

Growing Adoption in Chronic and Metabolic Disorders

Demand grows as chronic diseases drive clinicians to adopt therapies that offer predictable responses and fewer complications. Obesity, diabetes, and cardiovascular disorders push healthcare systems toward peptide-based interventions. Hospitals integrate peptide treatments into care plans that require targeted biological action. Drug makers develop formulations that support long-term patient compliance and safety. Regulatory agencies approve new peptide drugs that address critical gaps in metabolic care. Biotech firms enhance delivery systems that raise treatment stability. It gains wider acceptance as chronic disease cases continue to rise.

Advances in Peptide Manufacturing and CDMO Expansion

Manufacturers modernize platforms that support sterile, scalable, and cost-efficient peptide production across regulated facilities. CDMOs increase capacity to support complex synthesis steps required for high-purity peptides. Innovation in purification systems helps producers maintain strict quality benchmarks. Europe maintains strong GMP-compliant clusters that attract global drug developers. China invests in smart manufacturing lines that upgrade process efficiency. Pharmaceutical companies outsource production to reduce operational risk and accelerate development timelines. The China and Europe Peptide Market benefits from strong manufacturing infrastructure in both regions.

Market Trends:

Rising Shift Toward Long-Acting and Sustained-Release Peptide Formulations

Drug developers design formulations that extend therapeutic duration and reduce dosing frequency. Sustained-release designs help improve patient adherence in chronic conditions. Researchers advance delivery platforms that protect peptides from rapid breakdown. Hospitals show interest in long-acting options that lower treatment burden on patients. Europe invests in novel injectable formats that improve usability. China increases development activity in controlled-release technologies. The China and Europe Peptide Market observes stable demand for technologies that enhance treatment convenience.

For instance, Zealand Pharma’s fast-acting glucagon analog dasiglucagon (brand name Zegalogue®) reached regulatory milestones backed by pharmacokinetic data showing rapid action suitable for the acute treatment of severe hypoglycemia.

Growing Use of AI in Peptide Discovery and Design

AI-driven modeling tools help researchers identify structures with improved activity and stability. Predictive systems support rapid screening of thousands of peptide sequences. Labs shorten development cycles by combining machine learning with automated synthesis. Companies adopt digital workflows to reduce trial-and-error phases. Europe leads adoption due to strong digital innovation capacity. China grows quickly through investment in biotech AI platforms. It benefits from technologies that reduce cost and time in discovery processes.

For instance, Insilico Medicine used its AI platform to design peptide candidates by screening more than 10,000 structures computationally, cutting early discovery time by over 70%.

Rising Adoption in Personalized and Companion Diagnostics

Peptide biomarkers gain wider use in diagnostic kits that support disease detection and monitoring. Hospitals use peptide-based assays to support early diagnosis across oncology and metabolic categories. Labs integrate precision diagnostic tools that improve clinical decision accuracy. Companies expand portfolios of peptide reagents used in assay development. Europe adopts personalized medicine strategies supported by advanced diagnostic networks. China advances clinical diagnostics due to rising investment in precision healthcare. The China and Europe Peptide Market integrates peptides into broader personalized care pathways.

Growth in Injectable Drug Delivery and Novel Administration Routes

Injectable peptide therapies gain strong demand in therapeutic areas that require quick and targeted responses. Developers improve formulation viscosity and stability to support better administration. Needle-free delivery systems gain research interest for patient comfort. Companies investigate transdermal and oral delivery options that support expanded accessibility. Hospitals prefer formats that reduce procedural time. Europe advances delivery technology through strong research systems. China expands development in delivery innovation to support new peptide pipelines.

Market Challenges Analysis:

High Production Costs and Complex Manufacturing Constraints

Peptide synthesis requires strict process control, which raises cost pressure across production lines. Complex purification steps demand advanced equipment and skilled personnel. Manufacturers need strong GMP systems to maintain product integrity across large batches. China builds capability but faces scale-up challenges linked to high-purity materials. Europe deals with elevated operational expenses due to regulatory requirements. Companies struggle to balance speed and quality in production planning. It faces cost burdens that limit entry for smaller innovators. The China and Europe Peptide Market continues to manage financial strain tied to technical complexity.

Regulatory Variations and Compliance Barriers Across Regions

Developers navigate complex regulatory frameworks that differ between China and Europe. Approval timelines vary, which slows cross-regional commercialization plans. Documentation standards require extensive clinical evidence and quality data. Companies spend significant resources aligning manufacturing with region-specific requirements. Regulators scrutinize production systems to ensure safety and purity. Compliance delays impact launch timelines for new peptide drugs. Firms face hurdles adapting to evolving regulatory expectations. It must align development strategies with varied compliance structures across both regions.

Market Opportunities:

Growth Potential in Oncology, Metabolic, and Rare Disease Applications

Peptide therapeutics gain strong interest in cancer and metabolic disorders that require targeted action. Researchers develop sequences that support immune modulation and tumor inhibition. Hospitals adopt peptide regimens that offer safer alternatives to older drug classes. Biotech firms explore peptides for rare disease treatment due to strong specificity benefits. Europe strengthens precision oncology programs that integrate peptide therapy. China increases investment in research that supports rare disease care frameworks. The China and Europe Peptide Market can expand through broader therapeutic diversification.

Expansion of CDMO Partnerships and Advanced Delivery Platforms

CDMOs create opportunities through expanded manufacturing capacity and specialized synthesis lines. Drug developers use outsourced platforms to accelerate pipeline progression. Delivery technology innovation supports longer-acting formulations with better patient outcomes. Companies invest in smart manufacturing tools that reduce cost and improve consistency. Europe promotes collaboration between biotech and contract partners. China grows its outsourcing ecosystem through new high-tech facilities. It can capture growth by aligning with partners that support faster and more flexible development.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Market Segmentation Analysis:

By Peptide Type

The China and Europe Peptide Market shows strong diversification across peptide types that support cosmetic and personal care innovation. Signal peptides lead demand due to wide use in skin firmness and repair products. Neurotransmitter inhibitor peptides gain traction for wrinkle-relaxing formulations. Carrier peptides hold steady adoption because they boost nutrient delivery and skin performance. Enzyme inhibitor peptides support protective and anti-aging functions across premium lines. Structural peptides expand their presence in elasticity and barrier-strengthening products. Synthetic antimicrobial peptides rise in value through applications in hygiene and sensitive-skin ranges. Other peptide types cater to niche needs across evolving formulations.

For instance, DSM’s SYN-AKE peptide is backed by clinical data showing up to a 52% wrinkle-reduction effect within 28 days of regular use.

By Application

Hair, eyelash, and eyebrow care solutions gain strong traction as consumers seek targeted beauty outcomes. Whitening peptide products maintain high usage across Asia and Europe due to demand for tone correction. Anti-aging peptides secure the largest share due to their role in firmness and wrinkle care. Skin renewal peptides support exfoliation, regeneration, and texture enhancement. Anti-allergic and anti-inflammatory peptides find relevance in sensitive-skin products. Slimming and breast enhancement peptides serve specialized beauty categories. Other applications expand through rising interest in multifunctional cosmetic benefits.

By End Product

Skin care dominates demand due to high adoption of peptide-based serums, creams, and repair formulas. Hair care integrates peptides for strengthening and density-focused treatments. Eye care products gain steady interest as peptides support firmness and fine-line reduction around delicate areas. It benefits from diverse end-product integration across premium and mass-market lines.

By End User

Cosmetic manufacturers lead consumption because they integrate peptides into wide product portfolios. Cosmetic contract manufacturers (OEM/ODM) support large-scale production for global brands. Biopharmaceutical and personal care industries increase adoption through research-driven formulations and high-performance actives.

Segmentation:

By Peptide Type

Signal Peptides
Neurotransmitter Inhibitor Peptides
Carrier Peptides
Enzyme Inhibitor Peptides
Structural Peptides
Synthetic Antimicrobial Peptides (AMPs)
Others

By Application

Hair / Eyelash / Eyebrow Care Series (Peptides)
Whitening Series (Peptides)
Anti-Aging Series (Peptides)
Skin Renewal Series (Peptides)
Anti-allergic & Anti-inflammatory Series (Peptides)
Slimming & Breast Enhancement Series (Peptides)
Others

By End Product

Skin Care
Hair Care
Eye Care

By End User

Cosmetic Manufacturers
Cosmetic Contract Manufacturers (OEM/ODM)
Biopharmaceutical / Personal Care Industries

By Region

China
Europe
- UK
- France
- Germany
- Italy
- Spain
- Russia
- Belgium
- Netherlands
- Austria
- Sweden
- Poland
- Denmark
- Switzerland
- Rest of Europe

Regional Analysis:

China’s Market Position

China holds the largest share of the China and Europe Peptide Market, accounting for about 58 of total demand. Strong domestic manufacturing capacity supports rapid production of peptide ingredients used in skin, hair, and personal care formulations. Local brands invest in advanced actives that drive wider peptide adoption across mass and premium ranges. Government support for biotechnology strengthens research depth and pipeline expansion. OEM/ODM networks boost export potential, which improves the region’s competitive edge. Consumer interest in whitening, anti-aging, and repair solutions continues to raise peptide consumption. The China and Europe Peptide Market gains significant momentum from China’s strong innovation and manufacturing base.

Europe’s Market Performance

Europe contributes around 42% of the market, supported by high interest in premium cosmetic actives and dermatology-led formulations. Germany, France, and the UK lead demand due to strong personal care industries and advanced R&D ecosystems. European companies focus on high-purity peptides that fit strict regulatory and safety requirements. Brands adopt peptides across anti-aging, barrier-repair, and sensitive-skin lines that require evidence-backed performance. Local manufacturers leverage strong biotech capabilities, which support innovation in structural and functional peptides. Consumer preference for clinically validated ingredients strengthens regional adoption. It benefits from Europe’s mature regulatory landscape and strong emphasis on product efficacy.

Comparative Regional Dynamics

China remains the fastest-growing region due to scale, price flexibility, and strong OEM/ODM integration, while Europe sustains leadership in premium, research-intensive peptide solutions. China shows rapid expansion in hair, whitening, and multifunctional peptide applications, driven by shifting consumer preferences. Europe advances high-end anti-aging and repair-based formulations supported by dermatological research. Both regions expand production networks to meet rising demand from global cosmetic brands. Market shares reflect differing strengths: China leads with volume-driven growth, while Europe leads in scientific and regulatory excellence. The China and Europe Peptide Market achieves balanced expansion driven by complementary regional capabilities.

Key Player Analysis:

Zhejiang Peptides Biotech Co., Ltd
Lifeworth
Creative Peptides
Shijiazhuang Xindong Technology Service Co., Ltd
Koninklijke DSM NV (DSM)
Symrise AG
Croda International Plc
Merck KGaA
The Lubrizol Corporation
Ashland Inc.
Creative Peptides
Croda International Plc
Symrise AG
Ashland Inc.

Competitive Analysis:

The China and Europe Peptide Market features a competitive landscape shaped by strong R&D capabilities, advanced manufacturing networks, and expanding product portfolios. Leading players focus on high-purity actives that support performance-driven cosmetic and personal care lines. European companies emphasize stringent quality standards, while Chinese manufacturers scale production to meet global OEM/ODM demand. Firms invest in peptide innovation linked to anti-aging, whitening, and repair-focused applications. Strategic alliances strengthen technology access and help companies expand across both regions. Contract manufacturers gain traction through flexible production models. It maintains high competitiveness driven by innovation depth and regional specialization.

Recent Developments:

Symrise AG and Croda International Plc are leading innovation through sustainable peptide development, focusing on biomimetic and high-purity peptides for cosmetic applications. Croda International Plc has been highlighted in market reports as a major player in expanding bioengineered peptide portfolios and cross-industry collaborations around 2025, indicating active movement in partnerships and product development within the European peptide market.

Report Coverage:

The research report offers an in-depth analysis based on peptide type, application, end product, and end user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

Strong demand for high-performance actives is expected to push innovation across peptide categories.
Hair, whitening, and anti-aging applications will expand as consumer needs shift toward targeted solutions.
China will strengthen its position through scalable OEM/ODM production aligned with global brand requirements.
Europe will maintain leadership in evidence-based, dermatology-backed peptide development.
Manufacturing upgrades across both regions will improve purity, stability, and delivery outcomes.
Companies will increase collaborations to access advanced synthesis and bioengineering tools.
AI technologies will influence peptide discovery, reducing development timeframes.
End-user diversification will increase as biopharmaceutical and personal care industries adopt advanced actives.
New peptide formats will support premium positioning across skin, hair, and eye care lines.
Regulatory harmonization efforts may reduce approval times and simplify cross-regional commercialization.

CHAPTER NO. 1 : INTRODUCTION 20

1.1.1. Report Description 20

Purpose of the Report 20

USP & Key Offerings 20

1.1.2. Key Benefits for Stakeholders 20

1.1.3. Target Audience 21

1.1.4. Report Scope 21

CHAPTER NO. 2 : EXECUTIVE SUMMARY 22

2.1. Peptide Market Snapshot 22

2.1.1. China and Europe Peptide Market, 2018 – 2032 (Metric Tons) (USD Million) 24

2.2. Insights from Primary Respondents 24

CHAPTER NO. 3 : PEPTIDE MARKET – INDUSTRY ANALYSIS 25

3.1. Introduction 25

3.2. Market Drivers 26

3.2.1. Rising demand for high-performance actives & anti-aging solutions 26

3.2.2. Biotechnology and synthesis advancements 27

3.3. Market Restraints 28

3.3.1. High‐cost production & scalability issues 28

3.4. Market Opportunities 29

3.4.1. Market Opportunity Analysis 29

3.5. Porter’s Five Forces Analysis 30

3.6. Value Chain Analysis 31

3.7. Buying Criteria 32

CHAPTER NO. 4 : PRICE ANALYSIS 33

4.1. Price Analysis by Region 33

4.1.1. China and Europe Peptide Market Price, By Region, 2018 – 2023 33

4.1.2. China and Europe Peptide Type Market Price, By Region, 2018 – 2023 33

4.2. Price Analysis by Peptide Type 34

4.2.1. China and Europe Peptide Market Price, By Peptide Type, 2018 – 2023 34

4.2.2. China and Europe Peptide Type Market Price, By Peptide Type, 2018 – 2023 34

CHAPTER NO. 5 : ANALYSIS COMPETITIVE LANDSCAPE 35

5.1. Company Market Share Analysis – 2023 35

5.1.1. China and Europe Peptide Market: Company Market Share, by Volume, 2023 35

5.1.2. China and Europe Peptide Market: Company Market Share, by Revenue, 2023 36

5.1.3. China and Europe Peptide Market: Top 6 Company Market Share, by Revenue, 2023 36

5.1.4. China and Europe Peptide Market: Top 3 Company Market Share, by Revenue, 2023 37

5.2. China Peptide Market Company Volume Market Share, 2023 38

5.3. China Peptide Market Company Revenue Market Share, 2023 39

5.4. Europe Peptide Market Company Volume Market Share, 2023 40

5.5. Europe Peptide Market Company Revenue Market Share, 2023 41

5.6. Company Assessment Metrics, 2023 42

5.6.1. Stars 42

5.6.2. Emerging Leaders 42

5.6.3. Pervasive Players 42

5.6.4. Participants 42

5.7. Start-ups /SMEs Assessment Metrics, 2023 42

5.7.1. Progressive Companies 42

5.7.2. Responsive Companies 42

5.7.3. Dynamic Companies 42

5.7.4. Starting Blocks 42

5.8. Strategic Developments 43

5.8.1. Acquisitions & Mergers 43

New Product Launch 43

Regional Expansion 43

5.9. Key Players Product Matrix 44

CHAPTER NO. 6 : PESTEL & ADJACENT MARKET ANALYSIS 45

6.1. PESTEL 45

6.1.1. Political Factors 45

6.1.2. Economic Factors 45

6.1.3. Social Factors 45

6.1.4. Technological Factors 45

6.1.5. Environmental Factors 45

6.1.6. Legal Factors 45

6.2. Adjacent Market Analysis 45

CHAPTER NO. 7 : PEPTIDE MARKET – BY PEPTIDE TYPE SEGMENT ANALYSIS 46

7.1. Peptide Market Overview, by Peptide Type Segment 46

7.1.1. Peptide Market Volume Share, By Peptide Type, 2023 & 2032 47

7.1.2. Peptide Market Revenue Share, By Peptide Type, 2023 & 2032 47

7.1.3. Peptide Market Attractiveness Analysis, By Peptide Type 48

7.1.4. Incremental Revenue Growth Opportunity, by Peptide Type, 2024 – 2032 48

7.1.5. Peptide Market Revenue, By Peptide Type, 2018, 2023, 2027 & 2032 49

7.2. Signal Peptides 50

7.3. Neurotransmitter Inhibitor Peptides 51

7.4. Carrier Peptides 52

7.5. Enzyme Inhibitor Peptides 53

7.6. Structural Peptides 54

7.7. Synthetic Antimicrobial Peptides (AMPs) 55

7.8. Others 56

CHAPTER NO. 8 : PEPTIDE MARKET – BY APPLICATION SEGMENT ANALYSIS 57

8.1. Peptide Market Overview, by Application Segment 57

8.1.1. Peptide Market Volume Share, By Application, 2023 & 2032 58

8.1.2. Peptide Market Revenue Share, By Application, 2023 & 2032 58

8.1.3. Peptide Market Attractiveness Analysis, By Application 59

8.1.4. Incremental Revenue Growth Opportunity, by Application, 2024 – 2032 59

8.1.5. Peptide Market Revenue, By Application, 2018, 2023, 2027 & 2032 60

8.2. Hair / Eyelash / Eyebrow Care Series (Peptides) 61

8.3. Whitening Series (Peptides) 62

8.4. Anti-Aging Series (Peptides) 63

8.5. Skin Renewal Series (Peptides) 64

8.6. Anti-allergic & Anti-inflammatory Series (Peptides) 65

8.7. Slimming & Breast Enhancement Series (Peptides) 66

8.8. Others 67

CHAPTER NO. 9 : PEPTIDE MARKET – BY END PRODUCT SEGMENT ANALYSIS 68

9.1. Peptide Market Overview, by End Product Segment 68

9.1.1. Peptide Market Volume Share, By End Product, 2023 & 2032 69

9.1.2. Peptide Market Revenue Share, By End Product, 2023 & 2032 69

9.1.3. Peptide Market Attractiveness Analysis, By End Product 70

9.1.4. Incremental Revenue Growth Opportunity, by End Product, 2024 – 2032 70

9.1.5. Peptide Market Revenue, By End Product, 2018, 2023, 2027 & 2032 71

9.2. Skin Care 72

9.3. Hair Care 73

9.4. Eye Care 74

CHAPTER NO. 10 : PEPTIDE MARKET – BY END USER SEGMENT ANALYSIS 75

10.1. Peptide Market Overview, by End User Segment 75

10.1.1. Peptide Market Volume Share, By End User, 2023 & 2032 76

10.1.2. Peptide Market Revenue Share, By End User, 2023 & 2032 76

10.1.3. Peptide Market Attractiveness Analysis, By End User 77

10.1.4. Incremental Revenue Growth Opportunity, by End User, 2024 – 2032 77

10.1.5. Peptide Market Revenue, By End User, 2018, 2023, 2027 & 2032 78

10.2. Cosmetic Manufacturers 79

10.3. Cosmetic Contract Manufacturers (OEM/ODM) 80

10.4. Biopharmaceutical / Personal Care Industries 81

CHAPTER NO. 11 : PEPTIDE MARKET – CHINA 82

11.1. China 82

11.1.1. Key Highlights 82

11.1.2. China Peptide Market Volume, By Peptide Type, 2018 – 2023 (Metric Tons) 83

11.1.3. China Peptide Market Revenue, By Peptide Type, 2018 – 2023 (USD Million) 84

11.1.4. China Peptide Market Volume, By Application, 2018 – 2023 (Metric Tons) 85

11.1.5. China Peptide Market Revenue, By Application, 2018 – 2023 (USD Million) 86

11.1.6. China Peptide Market Volume, By End Product, 2018 – 2023 (Metric Tons) 87

11.1.7. China Peptide Market Revenue, By End Product, 2018 – 2023 (USD Million) 88

11.1.8. China Peptide Market Volume, By End User, 2018 – 2023 (Metric Tons) 89

11.1.9. China Peptide Market Revenue, By End User, 2018 – 2023 (USD Million) 90

CHAPTER NO. 12 : PEPTIDE MARKET – EUROPE 91

12.1. Europe 91

12.1.1. Key Highlights 91

12.1.2. Europe Peptide Market Volume, By Country, 2018 – 2032 (Metric Tons) 92

12.1.3. Europe Peptide Market Revenue, By Country, 2018 – 2023 (USD Million) 93

12.1.4. Europe Peptide Market Volume, By Peptide Type, 2018 – 2023 (Metric Tons) 94

12.1.5. Europe Peptide Market Revenue, By Peptide Type, 2018 – 2023 (USD Million) 95

12.1.6. Europe Peptide Market Volume, By Application, 2018 – 2023 (Metric Tons) 96

12.1.7. Europe Peptide Market Revenue, By Application, 2018 – 2023 (USD Million) 97

12.1.8. Europe Peptide Market Volume, By End Product, 2018 – 2023 (Metric Tons) 98

12.1.9. Europe Peptide Market Revenue, By End Product, 2018 – 2023 (USD Million) 99

12.1.10. Europe Peptide Market Volume, By End User, 2018 – 2023 (Metric Tons) 100

12.1.11. Europe Peptide Market Revenue, By End User, 2018 – 2023 (USD Million) 101

12.2. UK 102

12.3. France 102

12.4. Germany 102

12.5. Italy 102

12.6. Spain 102

12.7. Russia 102

12.8. Belgium 102

12.9. Netherland 102

12.10. Austria 102

12.11. Sweden 102

12.12. Poland 102

12.13. Denmark 102

12.14. Switzerland 102

12.15. Rest of Europe 102

CHAPTER NO. 13 : COMPANY PROFILES 103

13.1. Croda International Plc 103

13.1.1. Company Overview 103

13.1.2. Product Portfolio 103

13.1.3. Swot Analysis 103

13.1.4. Business Strategy 104

13.1.5. Financial Overview 104

China 105

13.2. Symrise AG 105

13.3. Croda International Plc 105

13.4. Ashland Inc. 105

13.5. Zhejiang Peptites Biotech Co., Ltd 105

13.6. Lifeworth 105

13.7. Creative Peptides 105

13.8. Shijiazhuang Xindong Technology Service Co., Ltd 105

13.9. Company 8 105

13.10. Company 9 105

13.11. Company 10 105

Europe 105

13.12. Koninklijke DSM NV (DSM) 105

13.13. Symrise AG 105

13.14. Croda International Plc 105

13.15. Merck KGaA 105

13.16. The Lubrizol Corporation 105

13.17. Ashland Inc. 105

13.18. Creative Peptides 105

13.19. Company 8 105

13.20. Company 9 105

13.21. Company 10 105

List of Figures

FIG NO. 1. China and Europe Peptide Market Volume & Revenue, 2018 – 2032 (Metric Tons) (USD Million) 24

FIG NO. 2. Porter’s Five Forces Analysis for China and Europe Peptide Market 30

FIG NO. 3. Value Chain Analysis for China and Europe Peptide Market 31

FIG NO. 4. China and Europe Peptide Market Price, By Region, 2018 – 2023 33

FIG NO. 5. China and Europe Peptide Market Price, By Peptide Type, 2018 – 2023 34

FIG NO. 6. Company Share Analysis, 2023 35

FIG NO. 7. Company Share Analysis, 2023 36

FIG NO. 8. Company Share Analysis, 2023 36

FIG NO. 9. Company Share Analysis, 2023 37

FIG NO. 10. Peptide Market – Company Volume Market Share, 2023 38

FIG NO. 11. Peptide Market – Company Revenue Market Share, 2023 39

FIG NO. 12. Peptide Market – Company Volume Market Share, 2023 40

FIG NO. 13. Peptide Market – Company Revenue Market Share, 2023 41

FIG NO. 14. Peptide Market Volume Share, By Peptide Type, 2023 & 2032 47

FIG NO. 15. Peptide Market Revenue Share, By Peptide Type, 2023 & 2032 47

FIG NO. 16. Market Attractiveness Analysis, By Peptide Type 48

FIG NO. 17. Incremental Revenue Growth Opportunity by Peptide Type, 2024 – 2032 48

FIG NO. 18. Peptide Market Revenue, By Peptide Type, 2018, 2023, 2027 & 2032 49

FIG NO. 19. China and Europe Peptide Market for Signal Peptides, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 50

FIG NO. 20. China and Europe Peptide Market for Neurotransmitter Inhibitor Peptides, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 51

FIG NO. 21. China and Europe Peptide Market for Carrier Peptides, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 52

FIG NO. 22. China and Europe Peptide Market for Enzyme Inhibitor Peptides, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 53

FIG NO. 23. China and Europe Peptide Market for Structural Peptides, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 54

FIG NO. 24. China and Europe Peptide Market for Synthetic Antimicrobial Peptides (AMPs), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 55

FIG NO. 25. China and Europe Peptide Market for Others, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 56

FIG NO. 26. Peptide Market Volume Share, By Application, 2023 & 2032 58

FIG NO. 27. Peptide Market Revenue Share, By Application, 2023 & 2032 58

FIG NO. 28. Market Attractiveness Analysis, By Application 59

FIG NO. 29. Incremental Revenue Growth Opportunity by Application, 2024 – 2032 59

FIG NO. 30. Peptide Market Revenue, By Application, 2018, 2023, 2027 & 2032 60

FIG NO. 31. China and Europe Peptide Market for Hair / Eyelash / Eyebrow Care Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 61

FIG NO. 32. China and Europe Peptide Market for Whitening Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 62

FIG NO. 33. China and Europe Peptide Market for Anti-Aging Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 63

FIG NO. 34. China and Europe Peptide Market for Skin Renewal Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 64

FIG NO. 35. China and Europe Peptide Market for Anti-allergic & Anti-inflammatory Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 65

FIG NO. 36. China and Europe Peptide Market for Slimming & Breast Enhancement Series (Peptides), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 66

FIG NO. 37. China and Europe Peptide Market for Others, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 67

FIG NO. 38. Peptide Market Volume Share, By End Product, 2023 & 2032 69

FIG NO. 39. Peptide Market Revenue Share, By End Product, 2023 & 2032 69

FIG NO. 40. Market Attractiveness Analysis, By End Product 70

FIG NO. 41. Incremental Revenue Growth Opportunity by End Product, 2024 – 2032 70

FIG NO. 42. Peptide Market Revenue, By End Product, 2018, 2023, 2027 & 2032 71

FIG NO. 43. China and Europe Peptide Market for Skin Care, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 72

FIG NO. 44. China and Europe Peptide Market for Hair Care, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 73

FIG NO. 45. China and Europe Peptide Market for Eye Care, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 74

FIG NO. 46. Peptide Market Volume Share, By End User, 2023 & 2032 76

FIG NO. 47. Peptide Market Revenue Share, By End User, 2023 & 2032 76

FIG NO. 48. Market Attractiveness Analysis, By End User 77

FIG NO. 49. Incremental Revenue Growth Opportunity by End User, 2024 – 2032 77

FIG NO. 50. Peptide Market Revenue, By End User, 2018, 2023, 2027 & 2032 78

FIG NO. 51. China and Europe Peptide Market for Cosmetic Manufacturers, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 79

FIG NO. 52. China and Europe Peptide Market for Cosmetic Contract Manufacturers (OEM/ODM), Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 80

FIG NO. 53. China and Europe Peptide Market for Biopharmaceutical / Personal Care Industries, Volume & Revenue (Metric Tons) (USD Million) 2018 – 2032 81

FIG NO. 54. China Peptide Market Volume & Revenue, 2018 – 2032 (Metric Tons) (USD Million) 82

FIG NO. 55. Europe Peptide Market Volume & Revenue, 2018 – 2032 (Metric Tons) (USD Million) 9

Request A Free Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Frequently Asked Questions:

What is the current market size for the China and Europe Peptide Market, and what is its projected size in 2032?

The China and Europe Peptide Market is valued at USD 23,264.09 million in 2024 and is projected to reach USD 63,952.52 million by 2032. The China and Europe Peptide Market shows strong long-term expansion driven by rising demand for advanced actives.

At what Compound Annual Growth Rate is the China and Europe Peptide Market projected to grow between 2024 and 2032?

The China and Europe Peptide Market is projected to grow at a CAGR of 12.56% during the forecast period. Growth reflects strong adoption across skin, hair, and personal care applications.

Which China and Europe Peptide Market segment held the largest share in 2024?

The anti-aging application segment held the largest share of the China and Europe Peptide Market in 2024. This segment dominates due to strong demand for firmness, wrinkle care, and repair-driven formulations.

What are the primary factors fueling the growth of the China and Europe Peptide Market?

The China and Europe Peptide Market grows due to rising demand for high-performance cosmetic actives, strong R&D investment, expanding OEM/ODM networks, and greater adoption of targeted peptide solutions.

Who are the leading companies in the China and Europe Peptide Market?

Key companies in the China and Europe Peptide Market include Croda International Plc, Symrise AG, Merck KGaA, Ashland Inc., and Zhejiang Peptides Biotech. These firms lead through strong research capabilities and advanced production infrastructure.

Which region commanded the largest share of the China and Europe Peptide Market in 2024?

China commanded the largest share of the China and Europe Peptide Market in 2024. Its leadership is supported by strong manufacturing capacity, expanding OEM/ODM operations, and growing demand for peptide-based beauty solutions.

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Related Reports

4D Bioprinting Market

The 4D Bioprinting Market size was valued at USD 86.88 Million in 2024 and is anticipated to reach USD 695.73 Million by 2032, at a CAGR of 29.7% during the forecast period.

Next Generation Sequencing Market

The Next Generation Sequencing market was valued at USD 13 billion in 2024 and is projected to reach USD 33.66 billion by 2032, growing at a compound annual growth rate (CAGR) of 13% during the forecast period.

Cell Dissociation Market

Cell Dissociation Market size was valued at USD 399.41 Million in 2024 and is anticipated to reach USD 1084.57 Million by 2032, at a CAGR of 13.3% during the forecast period.

Cell Culture Monitoring Biosensors Market

Cell Culture Monitoring Biosensors Market size was valued at USD 413.8 Million in 2024 and is anticipated to reach USD 906.56 Million by 2032, at a CAGR of 10.3% during the forecast period.

Black Soldier Fly Market

Black Soldier Fly Market size was valued at USD 339.67 million in 2024 and is anticipated to reach USD 2572.67 million by 2032, at a CAGR of 28.8% during the forecast period.

Americas And Europe Chagas Disease Drugs Market

Americas and Europe Chagas Disease Drugs Market size was valued USD 10637.5 million in 2024 and is anticipated to reach USD 18277.21 million by 2032, at a CAGR of 7% during the forecast period.

Membrane Bioreactor Systems Market

Membrane Bioreactor Systems Market size was valued at USD 3797.5 Million in 2024 and is anticipated to reach USD 6623.02 Million by 2032, at a CAGR of 7.2% during the forecast period.

Cell Separation Technologies Market

The Cell Separation Technologies Market was valued at USD 12 billion in 2024 and is projected to reach USD 31.15 billion by 2032, growing at a CAGR of 12.84% during the forecast period.

Biologic Imaging Reagents Market

Biologic Imaging Reagents Market size was valued at USD 19,457.5 million in 2024 and is anticipated to reach USD 34,624.62 million by 2032, growing at a CAGR of 7.47% during the forecast period.

Biological Product Manufacturing Market

Biological Product Manufacturing Market size was valued USD 34 billion in 2024 and is anticipated to reach USD 118.6 billion by 2032, at a CAGR of 16.8% during the forecast period.

Healthcare Payer Services Market

Healthcare Payer Services market size was valued at USD 71 billion in 2024 and is anticipated to reach USD 121.84 billion by 2032, at a CAGR of 6.9% during the forecast period.

Healthcare Nanotechnology Market

Healthcare Nanotechnology Market size was valued at USD 220 billion in 2024 and is anticipated to reach USD 583.31 billion by 2032, at a CAGR of 12.94% during the forecast period.

Licence Option

Single User

$3999

Multi User

$5999

Enterprise

$10999

Report delivery within 24 to 48 hours

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Request A Free Sample

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Trusted By

Request Sample